Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 53

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 53
---
 day immediately prior to the Subscription Date (as defined in the Series A Common Warrant Agreement).
The exercise price is subject to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and
splits, the number of shares of Common Stock issuable upon the exercise of the February 2024 PIPE Common Warrants will also be adjusted
so that the aggregate exercise price shall be the same immediately before and immediately after any such adjustment. On stockholder approval
for the issuance of shares underlying the warrants, granted April 30, 2024, the exercise price of the Series A Common Warrants was adjusted
to $2,780 per share, per the terms of the Securities Purchase Agreement.

The
Series A Common Warrants became exercisable beginning six months after the issuance date (the “Initial Exercisability Date”)
and expiring on the third anniversary of the Initial Exercisability Date. The Series A Common Warrants require “buy-in” payments
to be made by us for failure to deliver any shares of Common Stock issuable upon exercise.

If
at the time of exercise of the Series A Common Warrants, there is no effective registration statement registering the shares of the Common
Stock underlying the Series A Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If
we issue options, convertible securities, warrants, shares, or similar securities to holders of Common Stock, each holder of February
2024 PIPE Common Warrants has the right to acquire the same as if the holder had exercised its Series A Common Warrants. The holders
of Series A Common Warrants are entitled to receive any dividends paid or distributions made to our holders of Common Stock on an “as
if converted” basis.

23

The
Series A Common Warrants prohibit us from entering into specified fundamental transactions unless the Successor entity assumes all of
our obligations under the Series A Common Warrants under a written agreement before the transaction is completed. Upon specified corporate
events, a holder of Series A Common Warrants will thereafter have the right to receive upon exercise such shares, securities, cash, assets
or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate
event had the Series A Common Warrants been exercised immediately prior to the applicable corporate event. When there is a transaction
involving specified changes of control, a holder of Series A Common Warrants can request the Company to exchange the then unex